News stories recently posted—mostly by industry-friendly outlets—have heralded the appearance of a petition from the Drug Policy Alliance (DPA) urging President Trump to deschedule marijuana entirely from the Controlled Substances Act (CSA).
This is in large part a face-saving exercise: Even rescheduling will be a policy loss for the DPA. But the problems with the letter go much deeper. The DPA frames descheduling as the only path to ending federal criminalization. While the letter appeals to social justice and public health, it omits critical scientific, legal, and public safety realities.
Mainly, the DPA claims that “descheduling is the only way to truly end federal criminalization,” but this argument is built on a flawed foundation. Notably, the organization fails to distinguish between low-THC marijuana and today’s hyper-potent strains, which can contain 15–30% THC or higher. According to DEA data, THC concentrations have quadrupled since 1995, rising from 3.96% to 16.14% in 2022. This escalation renders modern marijuana pharmacologically distinct and far more harmful than any of its predecessors. Research links high-THC marijuana to psychosis, addiction (with 30% of daily users developing cannabis use disorder), and cognitive impairment, particularly in young users. Descheduling without potency safeguards would legitimize these dangerous products.
Furthermore, the DPA overlooks legal precedent. The Supreme Court’s 2005 decision in Gonzales v. Raich affirmed federal authority to regulate cannabis under the Commerce Clause. Descheduling would invite interstate trafficking of high-THC products, destabilizing states that maintain prohibition. Most glaringly, the DPA avoids acknowledging that descheduling would empower Big Marijuana to flood the market with addictive concentrates — such as 90% THC vapes — mirroring the predatory tactics of Big Tobacco.
The DPA argues that expungements and reinvestment in harmed communities will rectify past injustices, but this claim crumbles under scrutiny. In states like Colorado and California, which have had legalized marijuana for years, racial disparities in arrests persist. For example, Black residents still face higher rates of arrests for unlicensed sales, revealing the hollowness of the DPA’s equity promises.Moreover, legalization has primarily benefited corporate weed, not marginalized communities. In 2022, 23% of Colorado’s marijuana revenue came from the 9% of users with cannabis use disorder per the state’s public records, exposing a profit model literally based on addiction. The DPA’s platform also lacks demands for THC potency caps, which would mitigate mental health crises — a silence that aligns suspiciously with industry lobbyists opposing such restrictions. Notably, the DPA disregards studies showing that high-THC products disproportionately harm low-income communities, where addiction and psychosis rates are rising post-legalization.
The DPA’s letter echoes lobbying by groups like the American Rights and Reform PAC, which frames legalization as “freedom” while obscuring THC’s harms. Their petition omits peer-reviewed data on psychosis links, instead parroting industry talking points about “consumer choice.”
In other words, the DPA’s letter is a masterclass in cherry-picking. It demands descheduling while ignoring the explosion of high-THC products driving addiction and psychosis, the industry’s exploitation of social justice rhetoric, and the need for compromise. Federal policy must prioritize science — not corporate lobbying — to avert a public health catastrophe.
The DPA’s facade crumbles under scrutiny. Until they address THC potency, corporate influence, and enforcement realities, their campaign is not a call for justice — but a Trojan horse for Big Marijuana.